# Orthostatic Ex-Vivo Lung Perfusion (EVLP): A Proof of Concept

**Authors:** Massimo Boffini, Andrea Costamagna, Matteo Marro, Erika Simonato, Paola Cassoni, Luca Bertero, Vito Fanelli, Cristina Barbero, Luca Brazzi, Mauro Rinaldi

PMC · DOI: 10.3389/ti.2024.13178 · Transplant International · 2024-07-31

## TL;DR

This study tests a new EVLP dome design to improve lung preservation by addressing fluid accumulation in specific lung areas.

## Contribution

A novel tilting dome design for EVLP is introduced to enhance lung preservation by targeting fluid accumulation in dorsal areas.

## Key findings

- The new tilting dome design was tested for safety and feasibility in EVLP.
- The design aims to reduce fluid accumulation in the dorsal lung areas during EVLP.
- The study is a proof of concept for improving donor lung suitability for transplantation.

## Abstract

The key goal in lung donation remains the improvement of graft preservation with the ultimate objective of increasing the number and quality of lung transplants (LTx). Therefore, in recent years the field of graft preservation focused on improving outcomes related to solid organ regeneration and restoration. In this contest Ex-Vivo Lung Perfusion (EVLP) plays a crucial role with the purpose to increase the donor pool availability transforming marginal and/or declined donor lungs suitable for transplantation. Aim of this proof of concept is to test the safety, suitability and feasibility of a new tilting dome for EVLP designed considering the dorsal lung areas as the “Achilles’ heel” of the EVLP due to a more fluid accumulation than in the supine standard position.

## Full-text entities

- **Diseases:** atelectasis (MESH:D001261), edema (MESH:D004487), pulmonary edema (MESH:D011654), hemorrhage (MESH:D006470), end-stage lung diseases (MESH:D058625), ischemia-reperfusion injury (MESH:D015427), graft dysfunction (MESH:D055031), EVLP (MESH:C536830), acute respiratory failure (MESH:D012131), inflammatory (MESH:D007249), ARDS (MESH:D012128), DCD (MESH:D012769), congestion (MESH:D002311), gain (MESH:D015430), lung injury (MESH:D055370), micro-thrombosis (MESH:C536681), air leak (MESH:D004618), alveolar microhemorrhage (MESH:D002282), lung lesions (MESH:D008171), pleuro-parenchymal lesions (MESH:D002543)
- **Chemicals:** O2 (MESH:D010100), methylprednisolone (MESH:D008775), formaldehyde (MESH:D005557), H2O (MESH:D014867), polypropylene (MESH:D011126), paraffin (MESH:D010232), N2 (MESH:D009584), hematoxylin (MESH:D006416), CO2 (MESH:D002245), EVLP (-), eosin (MESH:D004801), heparin (MESH:D006493), Perfadex (MESH:C070005)
- **Species:** Sus scrofa (pig, species) [taxon 9823], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11321966/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11321966/full.md

## References

23 references — full list in the complete paper: https://tomesphere.com/paper/PMC11321966/full.md

---
Source: https://tomesphere.com/paper/PMC11321966